[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity

Rhea-AI Filing Summary

Jazz Pharmaceuticals (JAZZ) insider Patricia Carr, SVP and Chief Accounting Officer, reported option-related share transactions. On November 18, 2025, she exercised a non-qualified stock option covering 5,250 ordinary shares at an exercise price of $136.18 per share, increasing her direct shareholdings. On the same date, she reported two sales of ordinary shares: one for 69 shares at $181.66 per share and another for 5,250 shares at $182.07 per share. After these transactions, she directly owned 7,012 ordinary shares of Jazz Pharmaceuticals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Patricia

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/18/2025		S		69	D	$181.66	7,012(1)	D
Ordinary Shares	11/18/2025		M		5,250	A	$136.18	12,262	D
Ordinary Shares	11/18/2025		S		5,250	D	$182.07	7,012	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$136.18	11/18/2025		M			5,250	(2)	03/01/2027	Ordinary Shares	5,250	$0.0	0	D

Explanation of Responses:

1. The Reporting Person acquired 69 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025.

2. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2021.

	By: /s/Adam Guttmann, as attorney in fact For: Patricia Carr	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Jazz Pharmaceuticals (JAZZ) report for Patricia Carr?

The filing shows that Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported exercising stock options and selling ordinary shares on November 18, 2025.

How many Jazz Pharmaceuticals (JAZZ) shares did Patricia Carr sell?

On November 18, 2025, Patricia Carr reported two sales: 69 ordinary shares at $181.66 per share and 5,250 ordinary shares at $182.07 per share.

What stock options did Patricia Carr exercise in this Jazz Pharmaceuticals (JAZZ) Form 4?

She exercised a non-qualified stock option with an exercise price of $136.18 per share for 5,250 ordinary shares on November 18, 2025. The option was fully vested as of March 2, 2021.

How many Jazz Pharmaceuticals (JAZZ) shares does Patricia Carr own after the reported transactions?

Following the reported transactions, Patricia Carr directly owned 7,012 ordinary shares of Jazz Pharmaceuticals.

What plan governed the options in Patricia Carrs Jazz Pharmaceuticals (JAZZ) Form 4?

The options exercised for 5,250 ordinary shares were granted under Jazz Pharmaceuticals 2011 Equity Incentive Plan, with vesting completed by March 2, 2021.

What is the Section 423 Employee Stock Purchase Plan mentioned in the Jazz Pharmaceuticals (JAZZ) filing?

The filing notes that 69 ordinary shares were acquired by the reporting person under a Section 423 Employee Stock Purchase Plan on May 30, 2025, indicating prior share accumulation through that plan.